Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
48 hedge funds and large institutions have $12.3M invested in Sienna Biopharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 15 closing their positions.
16% less funds holding
Funds holding: 57 → 48 (-9)
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
66% less capital invested
Capital invested by funds: $36.4M → $12.3M (-$24M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.42M |
| 2 |
Millennium Management
New York
|
+$451K |
| 3 |
Renaissance Technologies
New York
|
+$440K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$143K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LM
Luminus Management
Houston,
Texas
|
-$2.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.86M |
| 3 |
BlackRock
New York
|
-$1.08M |
| 4 |
State Street
Boston,
Massachusetts
|
-$547K |
| 5 |
Morgan Stanley
New York
|
-$210K |
SNNA Hedge Fund Activity: Q2 2019 in Review
48 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q2 2019, worth a combined $12.3M — down 66% from $36.4M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SNNA and 8 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $1.42M. The largest seller was Luminus Management, exiting entirely with an estimated $2.2M sold.
- 48 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q2 2019, down from 57 in Q1 2019.
- Funds reported $12.3M of Sienna Biopharmaceuticals, Inc. stock for Q2 2019, down 66% quarter-over-quarter.
- 8 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q2 2019 and 15 closed out, a net change of -7 holders.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q2 2019 was Vanguard Group, an estimated $1.42M added.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q2 2019 was Luminus Management, an estimated $2.2M sold.
Based on aggregated 13F filings for Q2 2019.